Back to search

Aristotle University Of Thessaloniki (AUTH)

Συγκριτική μελέτη της χορήγησης της ορλιστάτης και της σιμπουτραμίνης σε παχύσαρκες γυναίκες με το σύνδρομο των πολυκυστικών ωοθηκών

Abstract

dc:description

Polycystic ovary syndrome is the most common endocrine disease in the female reproductive age population. The clinical characteristics of the syndrome include hormonal, metabolic and reproductive disorders, such as obesity, hirsutism, oligomenorrhea, anovulation and infertility. According to the revised Rotterdam criteria (2003), in order to diagnose polycystic ovary syndrome, at least two of the following three criteria must be met: clinical diagnosis of anovulation, biochemical hyperandrogenemia or hyperandrogenemia’s clinical manifestations, and polycystic ovarian morphology in the ultrasound control. Obesity usually accompanies PCOS at a rate close to 50% of women with the syndrome. It is predominantly androgenetic-type obesity, manifested by the accumulation of visceral-type fat and is often accompanied by hyperandrogenemia, hyperinsulinemia, insulin resistance and impaired glucose tolerance. The modern therapeutic approach to obesity involves balanced nutrition, physical exercise, psychological support, drug use and surgical treatment. In the present study, the treatment of obesity is based on low-caloric diet, physical activity and medication, through the administration of two drugs, orlistat and sibutramine. Orlistat is a drug that acts peripherally in the absorption of fat in food, causing reversible gastrointestinal lipase inhibition without affecting the activity of other enzymes such as trypsin, chymotrypsin, amylase and phospholipases. The effect of this selective action is the undisturbed absorption of carbohydrates, proteins and phospholipids. Additionally, administration of orlistat to obese people with polycystic ovary syndrome has been associated with a decrease in androgen levels, insulin and a decrease in insulin resistance markers. Sibutramine is a re-uptake inhibitor of nor-epinephrine and serotonin, with central action in the hypothalamus, where the center of saturation and the center of hunger are located. Sibutramine, by inhibiting re-uptake of nor-epinephrine and serotonin, increases postprandial saturation and energy consumption, thus retaining the fall in the underlying metabolism observed after weight loss. This study was designed to investigate the effect of weight loss, low-caloric diet, physical exercise and administration of orlistat and sibutramine for six months, on the anthropometric, hormonal and metabolic characteristics of overweight and obese patients with or without polycystic ovary syndrome, and comparing the two drugs for their therapeutic benefit with respect to the above parameters. We studied 196 overweight and obese patients with polycystic ovary syndrome. These women followed a weight loss program with low-caloric diet, physical exercise and administration of orlistat or sibutramine for 6 months. We also studied 21 overweight and obese women with normal ovulation cycles, without biochemical hyperandrogenemia or hyperandrogenemia’s clinical manifestations and without polycystic ovarian morphology in ultrasound, following a weight-loss program with low-caloric diet and physical exercise for 6 months.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2018

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Chatzis, Panagiotis
  • Χατζής, Παναγιώτης

Subjects

dc:subject × 6

Rights

dc:rights
Statement dc:rights
  • BY
Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/43479

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Chatzis, Panagiotis; Χατζής, Παναγιώτης. Συγκριτική μελέτη της χορήγησης της ορλιστάτης και της σιμπουτραμίνης σε παχύσαρκες γυναίκες με το σύνδρομο των πολυκυστικών ωοθηκών. Aristotle University Of Thessaloniki (AUTH), 2018. http://hdl.handle.net/10442/hedi/43479